Find Reports
Select Report Type
Reimbursement Review
Displaying 126 - 150 of 1430
Please scroll or swipe to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| nivolumab and relatlimab | Opdualag | nivolumab and relatlimab | unresectable or metastatic melanoma | Reimburse with clinical criteria and/or conditions | Complete | PC0329-000 | |||
| glofitamab | Columvi | glofitamab | Relapsed or refractory diffuse large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | PC0320-000 | |||
| sacituzumab govitecan | Trodelvy | sacituzumab govitecan | HR+, HER2− advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0323-000 | |||
| niraparib abiraterone acetate | Akeega | niraparib abiraterone acetate | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0326-000 | |||
| olaparib | Lynparza | olaparib | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0319-000 | |||
| vutrisiran | Amvuttra | vutrisiran | Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) | Reimburse with clinical criteria and/or conditions | Complete | SR0801-000 | |||
| Unresectable Hepatocellular Ca... | Unresectable Hepatocellular Carcinoma | Complete | PH0036-000 | ||||||
| evinacumab | Evkeeza | evinacumab | Homozygous familial hypercholesterolemia (HoFH) | Reimburse with clinical criteria and/or conditions | Complete | SR0778-000 | |||
| eltrombopag | N/A | eltrombopag | Severe Aplastic Anemia (SAA) | Reimburse with clinical criteria and/or conditions | Complete | SX0777-000 | |||
| ibrutinib | Imbruvica | ibrutinib | Waldenström’s Macroglobulinemia | Reimburse with clinical criteria and/or conditions | Complete | PC0328-000 | |||
| calaspargase pegol | Asparlas | calaspargase pegol | Acute lymphoblastic leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | PC0321-000 | |||
| bevacizumab and lomustine | N/A | bevacizumab and lomustine | Recurrent glioblastoma multiform | Reimburse with clinical criteria and/or conditions | Complete | PX0318-000 | |||
| polatuzumab vedotin | Polivy | polatuzumab vedotin | Large B-cell lymphoma | Do not reimburse | Complete | PC0313-000 | |||
| upadacitinib | Rinvoq | upadacitinib | Crohns disease | Reimburse with clinical criteria and/or conditions | Complete | SR0775-000 | |||
| efgartigimod alfa | Vyvgart | efgartigimod alfa | Generalized myasthenia gravis (gMG) | Reimburse with clinical criteria and/or conditions | Complete | SR0782-000 | |||
| HR+ HER2- Breast Cancer and Tr... | HR+ HER2- Breast Cancer and Triple Negative Breast Cancer, with inclusion of HER2 Low Breast Cancer | Complete | PH0033-000 | ||||||
| andexanet alfa | Ondexxya | andexanet alfa | Reversal of FXa inhibitor anticoagulant effects | Do not reimburse | Complete | ST0772-000 | |||
| NSCLC without actionable oncog... | Non-Small Cell Lung Cancer | Completed | PH0015-000 | ||||||
| elexacaftor/tezacaftor/ivacaft... | Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del CFTR mutation, 2 years and older | Reimburse with clinical criteria and/or conditions | Complete | SR0776-000 | |||
| somapacitan | Sogroya | somapacitan | Growth Hormone Deficiency (GHD) | Reimburse with clinical criteria and/or conditions | Complete | SR0779-000 | |||
| mirikizumab | Omvoh | mirikizumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | SR0773-000 | |||
| cabozantinib | Cabometyx | cabozantinib | Advanced or metastatic renal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0312-000 | |||
| durvalumab and tremelimumab | Imfinzi and Imjudo | durvalumab and tremelimumab | unresectable hepatocellular carcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0308-000 | |||
| ibrutinib | Imbruvica | ibrutinib | Chronic lymphocytic leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | PC0317-000 | |||
| rivaroxaban | N/A | rivaroxaban | Venous thromboembolic events (VTE) | Reimburse with clinical criteria and/or conditions | Complete | SX0750-000 - SR0750-000 |
Health Technology Review
Displaying 126 - 150 of 602
Please scroll or swipe to view the full content.
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 26 of 26
View All Reports
Displaying 126 - 150 of 2142
Please scroll or swipe to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| roflumilast | Reimbursement Review | Pending | SR0887-000 | ||||
| Appropriate Use of Antipsychotics in Long-Term Care | Health Technology Review | Technology Review | Active | HC0095-000 | |||
| trastuzumab deruxtecan | Reimbursement Review | Pending | PC0401-000 | ||||
| ciltacabtagene autoleucel | Reimbursement Review | Complete | PG0361-000 | ||||
| Urothelial carcinoma | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0070-000 | |||
| Midline Catheters for Administering Intravenous Infusion Therapy | Health Technology Review | Rapid Review | Completed | RC1572-000 | |||
| Calcitonin Gene-Related Peptide Inhibitors for Migraine Prophylaxis | Health Technology Review | Technology Review | Completed | HC0081-000 | |||
| tarlatamab | Reimbursement Review | Active | PC0351-000 | ||||
| upadacitinib | Reimbursement Review | Pending | SR0877-000 | ||||
| Switching Calcitonin Gene–Related Peptide Inhibitors for Migraine Prophylaxis | Health Technology Review | Peer-reviewed Summary with Critical Appraisal | Completed | RD0071-000 | |||
| cladribine | Reimbursement Review | Complete | SR0546-000 | ||||
| venetoclax | Reimbursement Review | Complete | PC0362-000 | ||||
| Natalizumab | Reimbursement Review | Complete | SR0133-000 | ||||
| inebilizumab | Reimbursement Review | Pending | SR0889-000 | ||||
| Trends in Opioid Prescribing in Canada, 2018-2022 | This study analyzed trends in prescription opioid use for pain and opioid agonist therapy from January 2018 to December 2022 across 6 Canadian provinces. | Health Technology Review | Technology Review | Completed | HC0071-000 | ||
| 2025 Watch List: Artificial Intelligence | The 2025 Watch List focuses on the use of artificial intelligence technologies in health care and the issues that may arise with the implementation of these technologies. | Horizon Scan | Roundup | Completed | ER0015-000 | ||
| danicopan | Reimbursement Review | Complete | SR0815-000 | ||||
| enfortumab vedotin | Reimbursement Review | Complete | PC0353-000 | ||||
| Planning for the Introduction of New CT Services in Rural and Remote Communities in Canada | We conducted an informal survey among senior medical imaging decision-makers to determine the factors that influence planning for new CT services in rural and remote communities in Canada. | Health Technology Review | CMII Service | Completed | CM0032-000 | ||
| Virtual Remote Imaging Services: CT and MRI Scanning | Health Technology Review | CMII Service | Active | CM0017-000 | |||
| momelotinib | Reimbursement Review | Active | PC0355-000 | ||||
| garadacimab | Reimbursement Review | Active | SR0860-000 | ||||
| Comparative Effectiveness of Real-Time Teleultrasound Versus In-Person Ultrasound | Health Technology Review | CMII Service | Completed | CM0024-000 | |||
| elexacaftor/tezacaftor/ivacaftor and ivacaftor | Reimbursement Review | Complete | SR0837-000 | ||||
| Non-small Cell Lung Cancer | Reimbursement Review | Provisional Funding Algorithm | Merged | PH0081-000 |
Provisional Funding Algorithm
Displaying 76 - 81 of 81